RedHawk (SNDD) 10-K 1 Nov 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Document And Entity Information
Entity Registrant Name	RedHawk Holdings Corp.
Entity Central Index Key	1,353,406
Document Type	10-K
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 2,174,709
Entity Common Stock, Shares Outstanding	361,049,027
Trading Symbol	IDNG
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Current Assets:
Cash	$ 53,939	$ 727,631
Marketable securities, at market value		339,032
Receivables	548,992	472,584
Inventory, at cost	364,331	113,795
Assets held for sale	745,854	761,521
Prepaid expenses	44,626	21,295
Total Current Assets	1,757,742	2,435,858
Other Assets
Investment in real estate limited partnership	625,000	625,000
Equity investment in and advances to limited liability companies		407,271
Intangible asset, net of amortization of $223,408 and $154,744, respectively	528,583	170,687
Total Other Assets	1,153,583	1,202,958
Total Assets	2,911,325	3,638,816
Current Liabilities:
Accounts payable and accrued liabilities	860,104	825,934
Liabilities on assets held for sale	251,252	259,703
Line of credit		1,000,495
Insurance notes payable	7,225	14,178
Total Current Liabilities	1,118,581	2,100,310
Long-Term Debt:
Due to related party	35,000
Convertible notes payable, net of $42,914 and $34,791 in deferred loan costs and unamortized beneficial conversion of $80,842 and $63,092 in 2017 and 2016, respectively	462,384	242,117
Total Long-Term Debt	497,384	242,117
Total Liabilities	1,615,965	2,342,427
Commitments and Contingencies
Stockholders' Equity (Deficit):
Common Stock, par value of $0.001 per share, 450,000,000 authorized shares; 379,070,562 and 375,094,082 issued and 361,049,027 and 357,072,547 outstanding at June 30, 2017 and 2016, respectively	379,071	375,094
Additional paid-in capital	1,254,889	1,192,283
Accumulated other comprehensive loss		(38,860)
Accumulated deficit	(3,243,543)	(2,646,026)
Total Stockholders' Equity (Deficit) Before Treasury Stock	1,308,962	1,372,491
Less, Treasury stock 18,021,535 shares, at cost	(76,102)	(76,102)
Total RedHawk Holdings Corp. Stockholders' Equity	1,232,860	1,296,389
Noncontrolling interest in foreign limited liability company	62,500
Total Stockholders' Equity	1,295,360	1,296,389
Total Liabilities and Stockholders' Equity	2,911,325	3,638,816
5% Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, 5,000 authorized shares and 2,723 and 2,490 issued and outstanding in 2017 and 2016 respectively:	1,579,425	1,240,000
5% Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, 5,000 authorized shares and 2,723 and 2,490 issued and outstanding in 2017 and 2016 respectively:	$ 1,339,120	$ 1,250,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Amortization of intangible assets	$ 223,408	$ 154,744
Deferred loan costs	42,914	34,791
Unamortized beneficial conversion	$ 80,842	$ 63,092
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	2,723	2,490
Preferred stock, shares outstanding	2,723	2,490
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	379,070,562	375,094,082
Common stock, shares outstanding	361,049,027	357,072,547
Treasury stock, shares	18,021,535	18,021,535
5% Series A Preferred Stock [Member]
Preferred stock, stated value per share	$ 1,072.12
Preferred stock, shares designated	2,750
Preferred stock, shares issued	1,473	1,240
Preferred stock, shares outstanding	1,473	1,240
5% Series B Preferred Stock [Member]
Preferred stock, stated value per share	$ 1,071.30
Preferred stock, shares designated	1,250
Preferred stock, shares issued	1,250	1,250
Preferred stock, shares outstanding	1,250	1,250

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues	$ 1,670,488	$ 29,450
Less, discounts	(740,629)
Revenues, net	929,859	29,450
Operating Expenses:
Costs of goods sold	191,881
Sales and marketing expenses	79,163	104,304
Professional fees	392,310	607,138
Management fees	60,000	487,128
Operating expenses	133,655	17,911
Depreciation and amortization	112,729	87,143
General and administrative	288,036	140,048
Total Operating Expenses	1,257,774	1,443,672
Net Income (Loss) from Operations	(327,915)	(1,414,222)
Other Income (Expense):
Expiration of indebtedness		156,697
Amortization of discount on convertible debentures	(24,250)	(3,908)
Gain (Loss) on foreign currency exchange	6,651	(55,038)
Gain (Loss) on the sale of assets	(4,052)	59,834
Dividend income	9,968	23,866
Interest expense	(68,084)	(35,189)
Total Other Income (Expense)	(79,767)	146,262
Consolidated Net Income (Loss)	(407,681)	(1,267,960)
Other comprehensive income (loss):
Unrecognized loss on marketable securities		(38,860)
Reclassification adjustment for sale of marketable securities	38,860
Consolidated Comprehensive Income (Loss)	(368,821)	(1,306,820)
Less, Net income attributable to noncontrolling interest	62,500
Net Loss attributable to RedHawk Holdings Corp.	(431,321)	(1,306,820)
Preferred Stock Dividends	(127,336)	(62,552)
Comprehensive Loss Available for Common Stockholders	$ (558,657)	$ (1,369,372)
Net Loss Per Share
Basic
Diluted
Weighted Average Shares Outstanding
Basic	359,650,168	359,815,765
Diluted	359,650,168	359,815,765

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (407,681)	$ (1,267,960)
Adjustments to reconcile net loss to net cash used in operations:
Amortization of intangibles	88,664	68,664
Amortization of discount on convertible debentures	24,250	3,908
Depreciation	15,667	18,479
Amortization of deferred loan costs	11,784
Loss on sale of marketable securities	10,318
Contributed management services		20,000
Expiration of indebtedness		(156,697)
Non-cash interest expense	36,139
Changes in operating assets and liabilities:
Accounts receivable	(279,412)	(471,974)
Inventory	(249,933)	(104,039)
Prepaid expense and deposits	(23,030)	(21,295)
Accounts payable and accrued liabilities	59,770	737,954
Net Cash Used in Operating Activities	(154,640)	(1,172,960)
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from the sale of marketable securities	367,575	1,477,800
Intangible assets acquired		(5,000)
Investment in EcoGen	(356,152)	(147,170)
Net Cash Provided by Investing Activities	11,423	1,325,630
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party line of credit	285,000	71,365
Proceeds from the sale of stock	5,950	50,000
Proceeds from issuance of convertible notes	210,000	340,000
Proceeds from issuance of Series B preferred stock		256,765
Proceeds from exercise of warrants	18,632
Deferred loan costs, net	(19,907)	(34,791)
Preferred stock dividends declared but not paid		(62,552)
Proceeds from bank line of credit		20,495
Principal payments on bank line of credit	(1,000,495)
Net proceeds from insurance notes payable		14,178
Principal payments on insurance notes payable	(6,953)
Treasury stock acquired	0	(76,102)
Principal payments on long-term debt	(8,451)	(5,297)
Net Cash (Used in) Provided by Financing Activities	(516,224)	574,061
Effect of exchange rate on cash	(14,251)
Increase (Decrease) in cash	(673,692)	726,731
Cash, Beginning of Period	727,631	900
Cash, End of Period	53,939	727,631
Non-Cash Investing and Financing Activities:
Land and building acquired in exchange for Series A Preferred Stock and assumption of debt		780,000
Assumption of debt for land and building acquired		265,000
Exchange of marketable securities and assumption of line of credit for Series B Preferred Stock		1,855,692
Assumption of debt in exchange for marketable securities acquired		980,000
Partnership investment acquired in exchange for Series A Preferred Stock		625,000
Equity investment acquired in exchange for common stock		260,000
Related party line of credit converted into Series A Preferred Stock	250,000	100,000
Preferred stock dividends paid in kind	158,462	61,208
Beneficial conversion discount on convertible notes	42,500
Supplemental Disclosures:
Interest paid	56,300
Income tax paid

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total
Balance at Jun. 30, 2015			$ 360,094	$ 927,826			$ (1,315,615)		$ (27,695)
Balance, shares at Jun. 30, 2015			360,094,082
Net loss							(1,267,960)		(1,267,960)
Contributed management services				20,000					20,000
Sale of unregistered securities		$ 250,000	$ 5,000	45,000					300,000
Sale of unregistered securities, shares		250	5,000,000
Acquisitions: Commercial real estate	$ 215,000								215,000
Acquisitions: Commercial real estate, shares	215
Acquisitions: Investment in real estate partnership	$ 625,000								625,000
Acquisitions: Investment in real estate partnership, shares	625
Acquisitions: Corporate office	$ 300,000								300,000
Acquisitions: Corporate office, shares	300
Acquisitions: Equity investment in limited liability corporation			$ 10,000	250,000					260,000
Acquisitions: Equity investment in limited liability corporation, shares			10,000,000
Working capital contribution		$ 1,000,000		(117,543)					882,457
Working capital contribution, shares		1,000
Conversion of shareholder line of credit	$ 100,000								100,000
Conversion of shareholder line of credit, shares	100
Re-purchase of securities								$ (76,102)	(76,102)
Re-purchase of securities, shares								18,021,535
Fair value of beneficial conversion feature on convertible notes				67,000					67,000
Preferred stock dividends declared							(62,552)		(62,552)
Unrecognized loss on marketable securities					(38,860)				(38,860)
Reclassification adjustment for sale of marketable securities
Balance at Jun. 30, 2016	$ 1,240,000	$ 1,250,000	$ 375,094	1,192,283	(38,860)		(2,646,026)	$ (76,102)	1,296,389
Balance, shares at Jun. 30, 2016	1,240	1,250	375,094,082					18,021,535
Net loss						62,500	(470,181)		(407,681)
Conversion of shareholder line of credit	$ 233								250,000
Conversion of shareholder line of credit, shares	250,000
Fair value of beneficial conversion feature on convertible notes				42,000					42,000
Preferred stock dividends declared							(127,336)		(127,336)
Unrecognized loss on marketable securities
PIK Dividends	89,425	89,120							178,545
Reclassification adjustment for sale of marketable securities					38,860				38,860
Milito shares issued			$ 250	5,700					5,950
Milito shares issued, shares			250,000
Warrant exercise			$ 3,727	14,906					18,633
Warrant exercise, shares			3,726,480
Balance at Jun. 30, 2017	$ 1,579,425	$ 1,339,120	$ 379,071	$ 1,254,889		$ 62,500	$ (3,243,543)	$ (76,102)	$ 1,295,360
Balance, shares at Jun. 30, 2017	1,473	1,250	379,070,562					18,021,535

Nature of Operations and Contin

Nature of Operations and Continuance of Business	12 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Continuance of Business	1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS RedHawk Holdings Corp. (formerly Independence Energy Corp.) was incorporated in the State of Nevada on November 30, 2005 under the name “Oliver Creek Resources Inc.” At inception, we were organized to acquire, explore and develop natural resource properties in the United States. Effective August 12, 2008, we changed our name from “Oliver Creek Resources Inc.” to “Independence Energy Corp.” and opened for trading on the Over-the Counter Bulletin Board under the symbol “IDNG.” Effective October 13, 2015, by vote of a majority of the Company’s stockholders, the Company’s name was changed from “Independence Energy Corp.” to “RedHawk Holdings Corp.” On March 31, 2014, the Company acquired the exclusive right to distribute certain medical devices and changed the focus of its operations to include medical device distribution. We have expanded our business focus to include other operations. Currently, we are a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD™ Insulin Needle Destruction Unit (formerly known as the Disintegrator™), the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Through our United Kingdom based subsidiary, we manufacture, and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials” and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. The Company also holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner. Our real estate leasing revenues are generated from a commercial property under a long-term lease. Additionally, the Company’s real estate investment unit holds a limited liability company interest in a commercial restoration project in Hawaii. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will not be able to continue as a going concern without further financing. Currently, the Company must continue to realize its assets to discharge its liabilities in the normal course of business. The Company has generated limited revenues to date and has never paid any dividends on its common stock and is unlikely to pay any common stock dividends or generate significant earnings in the immediate or foreseeable future. For the year ended June 30, 2017, the Company had a consolidated net loss of $407,681 on net revenues of $929,859 and used $154,640 of cash in operating activities. As of June 30, 2017, the Company had cash of $53,939, working capital of $639,161 and an accumulated deficit of $3,243,543 including preferred stock dividends. The continuation of the Company as a going concern is still dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, cash proceeds from the sale of assets and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements of the Company as of June 30, 2017 and 2016 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost. Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Revenue Recognition We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials” and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. Our real estate leasing revenues are from certain commercial properties under long-term lease. The financial service revenue is from brokerage services earned in connection with debt placement services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and deducted from gross revenues and recorded as deferred revenue. Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. Marketable Securities We determine the appropriate classification of our marketable securities at the time of purchase and reassess the appropriateness of the classification at each reporting date. At June 30, 2016, all marketable securities held by the Company have been classified as available-for-sale and, as a result, are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income or loss. Realized gains and losses on the sale of marketable securities are determined on a specific identification basis. Interest and dividend income is recorded when it is earned and deemed realizable by the Company. At June 30, 2016, the fair value of the marketable securities on hand, which consisted entirely of widely recognized publicly-traded securities, was $339,032. Gross unrealized loss on the fair market value of the marketable securities was $38,860 as of June 30, 2016. As of June 30, 2016, we had trade date receivables of $302,288 recorded which was related to a sale of securities that had a trade date prior to June 30, 2016 and a settlement date after that date. The Company did not hold any marketable equity securities at June 30, 2017. Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2017 and June 30, 2016. Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method. Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the twelve-month period ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, we have reclassified the net book value of those properties along with related mortgage notes are reflected as assets and liabilities held for sale in the balance sheets. All such amounts are included in the land and hospitality segment. We expect the sale of those properties to occur in the fiscal year ending June 30, 2018 and have, accordingly, presented the held for sale assets and liabilities as current. The comparable June 30, 2016 balances have also been reclassified held for sale related assets and liabilities. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of June 30, 2017. We are also pursuing the sale of our real estate limited partnership investment, but we cannot conclude such a transaction would occur within one year and, therefore, have not reclassified related assets and liabilities as held for sale. Effective July 1, 2017, the Chemin Metairie Road property is leased under a one-year term at a rent of $1,500 per month. The lessee has an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. Although, there is no certainty that such sale will occur, we do believe the lessee will exercise that purchase option. The tenant that leases the Jefferson Street property has renewed that lease through December 31, 2022 as a rent of $3,500 per month. We continue to offer that property for sale and expect a sale to occur in our 2018 fiscal year. Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes, Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At June 30, 2017, including accrued but unpaid interest, there were 39,075,990 shares issuable upon conversion of the notes. Also at June 30, 2017, including accrued but unpaid dividends, there were potentially 105,295,000 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 133,911,979 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive. Comprehensive Income (Loss) ASC 220, Comprehensive Income Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company had marketable securities with a fair market value of $339,032 at June 30, 2016 which are all publicly traded securities with quoted prices in active markets. The fair value is based on Level 1 assumptions. The Company held no marketable securities as of June 30, 2017. The Company’s financial instruments consist principally of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. We do not expect that adoption will have a material impact on our financial position, results of operations, cash flows or disclosures. Debt Issuance Costs In April 2015, the FASB issued new guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. Therefore, the amortization of such costs will continue to be calculated using the interest method and be reported as interest expense. The new guidance does not specifically address, and therefore does not affect, the balance sheet presentation of debt issuance costs for revolving debt arrangements. This new guidance was effective for the Company in the first quarter of fiscal 2017, and applied on a retrospective basis. To date, our unamortized debt issuance cost was $42,914 and $34,791 as of June 30, 2017 and 2016, respectively. As the Company continues to raise capital to execute its growth strategy, the use of debt in the future may have additional issuance costs to be accounted for under this guidance. Leases In February 2016, the FASB issued ASU 2016-02, Leases

Other Assets

Other Assets	12 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other Assets	3. OTHER ASSETS On December 31, 2015, RedHawk Land & Hospitality, LLC acquired from Beechwood Properties, LLC 280,000 Class A Units (approximately a 2.0% membership interest) of fully paid, non-assessable units of limited liability company interest in Tower Hotel Fund 2013, LLC, a real estate development limited liability company formed in the state of Hawaii for acquisition, restoration and development of the Naniloa Hilo Resort in Hilo, Hawaii. The $625,000 purchase price was paid by the issuance of 625 shares of the Company’s Series A Preferred Stock. The purchase price was determined by an independent third-party valuation. Beechwood Properties, LLC is a real estate limited liability company owned and controlled by G. Darcy Klug, a stockholder and Chief Financial Officer and Chairman of the board of directors of the Company. This investment in real estate limited partnership is recorded at cost and the Company is not aware of any indicator of impairment as of June 30, 2017 and 2016. It is not practicable for the Company to estimate fair value of this investment. On March 23, 2016, RedHawk Pharma UK Ltd initially acquired a 25% equity interest in EcoGen Europe Ltd (which we refer to as “EcoGen”) from Scarlett Pharma Ltd (which we refer to herein as “Scarlett”). On September 12, 2017 we completed a share transfer agreement wherein we increased our ownership in EcoGen to 75%. Additionally, the Company has agreed in principal with Scarlett and its affiliate (“Agreement”) for the Company to further increase its ownership in EcoGen. Under the terms of the Agreement, Scarlett and its affiliate have agreed to surrender ten (10) million shares of RedHawk common stock, transfer to RedHawk approximately $300,000 of EcoGen preferred stock and other consideration in exchange for RedHawk assuming approximately $370,000 of obligations due to EcoGen. Throughout the fiscal year ended June 30, 2017, we have consolidated the accounts of EcoGen in our financial statements as we continue to exercise greater influence over EcoGen’s business affairs. At June 30, 2017, we again reassessed our position and again concluded that EcoGen is a VIE and the Company has the power to direct the activities of EcoGen and we have concluded that we are the primary beneficiary of EcoGen. This resulted in the recognition of approximately $450,000 in intangible assets related to licenses held by EcoGen. This allocation is preliminary and may be adjusted as we complete the evaluation of such assets; such intangible assets are being amortized over an estimated useful life of 20 years. Subsequent to June 30, 2017, we completed a share transfer agreement wherein we increased our ownership position in EcoGen to 75%. At the date of this filing, further agreements to increase our ownership position in EcoGen are being completed. On September 26, 2016, the Company announced it had agreed to acquire up to a 25% interest in Marlin USA Energy Partners, LLC (“Marlin”), the minority owner of Tigress Energy Partners, LLC. In exchange for a $70,000 cash investment related to this agreement, the Company received a 3.5% interest in Marlin. This investment was accounted for at cost. On April 12, 2017, the Company sold its investment in Marlin for $70,000 cash with no resulting gain or loss.

Loan and Insurance Note Payable

Loan and Insurance Note Payable	12 Months Ended
	Jun. 30, 2017
Loans Payable [Abstract]
Loan and Insurance Note Payable	4. LOAN AND INSURANCE NOTE PAYABLE We finance a portion of our insurance premiums. At June 30, 2017, the outstanding balance due on our premium finance agreements was $7,225.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	5. RELATED PARTY TRANSACTIONS Effective December 1, 2016, the Company entered into a $250,000 Commercial Note Line of Credit (which we refer to as the “Line of Credit”) with a stockholder and officer of the Company to evidence prior indebtedness and provide for future borrowings. The advances are used to fund our operations. The Line of Credit accrues interest at 5% per annum and matures on March 31, 2018. At maturity, or in connection with a pre-payment, subject to the conditions set forth in the Line of Credit, the stockholder has the right to convert the amount outstanding (or the amount of the prepayment) into the Company’s Series A Preferred Stock at the par value of $1,000 per share. During the year ended June 30, 2017, $250,000 of the amounts loaned under this line of credit were converted to preferred stock. At June 30, 2017, the principal balance totaled $35,000. The amount is included in noncurrent liabilities based on the expectation that either the Line of Credit maturity date will be extended or the amount outstanding will be converted to preferred stock as allowed for in the agreement. During the year ended June 30, 2017, EcoGen had sales to customers which are controlled by individuals which are shareholders of EcoGen and are the noncontrolling interests in our consolidated financial statements. These sales totaled $1,241,000 on a gross basis and had discounts of $968,000. A portion of these discounts were at levels that exceeded discounts offered to unaffiliated customers. During the quarter ended March 31, 2017, management of RedHawk and these noncontrolling shareholders of EcoGen reached an agreement whereby $370,000 of such discounts are to be considered an account receivable due to EcoGen by this affiliated customer. Subsequent to June 30, 2017, the Company has agreed to assume the obligations of these noncontrolling shareholders due to EcoGen in exchange for the transfer of approximately $300,000 of EcoGen preferred stock, 10 million shares of our outstanding common stock and other consideration. This agreement is in the process of being finalized as of the date of this filing. Beginning in the quarter ended March 31, 2017, certain members of management agreed to forego management fees in consideration of the operating cash flow needs of the Company. There is not a set timeline to reinstitute such management fees.

Long-term Debt, Debentures and

Long-term Debt, Debentures and Line of Credit	12 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Long-term Debt, Debentures and Line of Credit	6. LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT We have authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Convertible Notes”). The Convertible Notes are secured by certain Company real estate holdings and real estate holdings of a stockholder. The Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes. The Company may only issue the notice of its intent to redeem the Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Convertible Notes has the right to convert all or any portion of the Convertible Notes at the conversion price at any time prior to redemption. At June 30, 2017, there were $586,140 ($462,384 net of deferred financing costs and beneficial conversion option) of Convertible Notes outstanding, including $36,140 of interest paid in kind, which are convertible into our common stock at a conversion rate of $0.015 per share or 39,075,990 shares. We had a $1,000,000 line of credit with a bank of which $1,000,495 was outstanding as of June 30, 2016. The line of credit was due upon demand and was secured by marketable securities, a corporate guarantee and the guarantee of a stockholder who is also an officer of the Company. During the twelve-month period ended June 30, 2017, the outstanding balance on the line of credit was paid in full.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. COMMITMENTS AND CONTINGENCIES On January 31, 2017, the Company and a stockholder filed a complaint (the “Complaint”) in the United States District Court for the Eastern District of Louisiana (RedHawk Holdings Corp. and Beechwood Properties, LLC Case No. 2:17-cv-819). The Complaint names Daniel J. Schreiber (“Schreiber”) and the Schreiber Living Trust – DTD 2/08/96 (the “Schreiber Trust”) as defendants. Schreiber is the former Chief Executive Officer and director of RedHawk. The Schreiber Trust, of which Schreiber is the Trustee, is a shareholder of the Company. The Complaint lodged claims on behalf of RedHawk for securities fraud, fraud, and Schreiber’s breach of fiduciary duties. On April 24, 2017, RedHawk and its shareholder filed an amended complaint (“Amended Complaint”) naming Schreiber as the only proper defendant in the suit, individually and as Trustee of the Schreiber Trust. On May 22, 2017, Schreiber filed a motion to dismiss, or in the alternative to transfer, the suit on the grounds of lack of personal jurisdiction and improper venue. After the parties filed an opposition and reply, on August 16, 2017 the court denied the motion. On September 13, 2017, Schreiber filed an answer to the Amended Complaint, as well as counterclaims against RedHawk, Beechwood, and a director of RedHawk for actions allegedly taken in the course of his duty as a director. The counterclaims against RedHawk and its director are for alleged violation of UCC § 8-401, breach of fiduciary duty, negligence, and unfair trade practices. The legal remedies sought in these counterclaims were the subject of a lawsuit filed previously by Schreiber in the United States District Court for the Sothern District of California on April 24, 2017 (Case No. 3:17-cv-8824). At the time of the answer of the Louisiana lawsuit, the California action was still pending, and the answer asked that the counterclaim filed in Louisiana be stayed until the California case was adjudicated. On September 26, 2017, the court in the California action granted RedHawk’s motion to dismiss that suit. On October 10, 2017 a scheduling conference was held. The parties agreed to, among other matters, to exchange documents and conduct other discovery, and to schedule a bench trial starting June 11, 2018. RedHawk plans to vigorously contest the claims against it in this matter and to pursue the claims against Schreiber, individually and as Trustee of the Schreiber Trust.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2017
Stockholders' Equity (Deficit):
Stockholders' Equity	8 . STOCKHOLDERS’ EQUITY Effective on October 13, 2015, we amended and restated our articles of incorporation as previously adopted by a majority vote of our stockholders. The amended and restated articles of incorporation, among other things, changed our name to RedHawk Holdings Corp., authorized 5,000 shares of Preferred Stock, and increased the number of authorized shares of common stock from 375,000,000 to 450,000,000. Preferred Stock Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After six months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, originally with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After six months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends. Warrants During November 2014, we completed a private equity sale of 14,905,918 shares of common stock generating proceeds of $49,900. As a component of this private equity sale, 7,452,959 warrants to acquire common stock of the Company were also issued with an exercise price of $0.005 per share. During the twelve-month period ended June 30, 2017, 3,726,480 warrants were exercised, and the remaining warrants expired.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES As of June 30, 2017 and 2016, the Company had approximately $2,800,000 and $2,300,000, respectively, of U.S. net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2037. The related deferred income tax asset of these net operating losses is estimated to be approximately $1,000,000 and $800,000 as of June 30, 2017 and 2016, respectively. However, there is no net tax asset recorded as of June 30, 2017 or June 30, 2016 as a 100% valuation allowance has been established for the tax benefit generated. EcoGen also has a net operating loss as of June 30, 2017 for which no deferred tax asset has been provided. The Company accounts for interest and penalties relating to uncertain tax provisions in the current period statement of operations, as necessary. The Company has never filed a tax return. In order to utilize the available net operating loss carryforwards, the Company will need to prepare and file all tax returns since its inception. The Company’s tax years from inception are subject to examination. Due to our history of operating losses and the uncertainty surrounding the realization of the deferred tax assets in future years, our management has determined that it is more likely than not that the deferred tax assets will not be realized in future periods. Accordingly, the Company has recorded a valuation allowance against its net deferred tax assets.

Segment Information

Segment Information	12 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Information	10. SEGMENT INFORMATION SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information,” MEDICAL Twelve months ended LAND & DEVICE & OTHER June 30, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 39,000 $ 1,631,488 $ - $ - $ 1,670,488 Operating revenues, net $ 39,000 $ 890,859 $ - $ - $ 929,859 Operating income (loss) $ (2,223 ) $ 191,291 $ (32,732 ) $ (484,251 ) $ (327,915 ) Interest expense $ 27,221 $ 769 $ - $ 40,094 $ 68,084 Depreciation and amortization $ 15,666 $ 97,063 $ - $ - $ 112,729 Identifiable assets $ 1,381,622 $ 739,567 $ 240 $ 789,896 $ 2,911,325 MEDICAL Twelve months ended LAND & DEVICE & OTHER June 30, 2016 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 24,700 $ - $ 4,750 $ - $ 29,450 Operating income (loss) $ (5,364 ) $ (521,025 ) $ (22,881 ) $ (864,952 ) $ (1,414,222 ) Interest expense $ 9,843 $ - $ - $ 25,346 $ 35,189 Depreciation and amortization $ 18,479 $ 68,664 $ - $ - $ 87,143 Identifiable assets $ 1,396,780 $ 917,902 $ 5,529 $ 1,318,605 $ 3,638,816

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	11. SUBSEQUENT EVENTS The Company evaluates subsequent events through the time of our filing on the date we issue our financial statements, which was on October 31, 2017. The following are matters which occurred subsequent to June 30, 2017: ● Subsequent to June 30, 2017, we have agreed to a share transfer agreement with Scarlett Pharma Ltd whereby we increased our ownership of EcoGen Europe Ltd to 75%. Additionally, we have agreed in principle that in exchange for the assumption of approximately $370,000 of obligations due to EcoGen, we will receive 10,000,000 shares of our previously issued common stock, approximate $300,000 of EcoGen’s preferred stock and other consideration. This agreement is in the process of being finalized as of the date of this filing. ● Subsequent to year end, we executed a non-binding letter of intent to acquire a portfolio of European (“EU”) hospital injectable anti-infective branded generic licenses for the ultimate issuance of market authorizations in up to twelve (12) EU markets for seven core anti-infective products including piperacillin-tazobactam (PipTaz), meropenem, imipenem/cilastatin and the four (4) most widely used cephalosporins. The purchase price will be paid from future cash flows of the business.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of the Company as of June 30, 2017 and 2016 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost.
Use of Estimates	Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of investments and long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Revenue Recognition	Revenue Recognition We derive revenue from several types of activities – medical device sales, branded generic pharmaceutical sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals, certain other generic pharmaceuticals known as “specials” and certain pharmaceuticals outside of the United Kingdom’s National Health Service drug tariff referred to as NP8’s. Our real estate leasing revenues are from certain commercial properties under long-term lease. The financial service revenue is from brokerage services earned in connection with debt placement services. The Company offers customer discounts in certain cases. Such discounts are estimated at time of product sale and deducted from gross revenues and recorded as deferred revenue.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents.
Marketable Securities	Marketable Securities We determine the appropriate classification of our marketable securities at the time of purchase and reassess the appropriateness of the classification at each reporting date. At June 30, 2016, all marketable securities held by the Company have been classified as available-for-sale and, as a result, are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income or loss. Realized gains and losses on the sale of marketable securities are determined on a specific identification basis. Interest and dividend income is recorded when it is earned and deemed realizable by the Company. At June 30, 2016, the fair value of the marketable securities on hand, which consisted entirely of widely recognized publicly-traded securities, was $339,032. Gross unrealized loss on the fair market value of the marketable securities was $38,860 as of June 30, 2016. As of June 30, 2016, we had trade date receivables of $302,288 recorded which was related to a sale of securities that had a trade date prior to June 30, 2016 and a settlement date after that date. The Company did not hold any marketable equity securities at June 30, 2017.
Accounts Receivable	Accounts Receivable Accounts receivables are amounts due from customers of our pharmaceutical, medical device and financial services divisions. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2017 and June 30, 2016.
Inventory	Inventory Inventory consist of purchased thermometers, an advanced bleeding control, non-compression hemostasis, a patented antimicrobial ionic silver calcium catheter dressing, and certain branded generic pharmaceuticals held for resale. All inventories are stated at the lower of cost or net realizable value utilizing the first-in, first-out method.
Property and Improvements	Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight-line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years. During the twelve-month period ended June 30, 2017, we decided to sell our Louisiana real estate holdings, which includes our former corporate headquarters on Chemin Metairie Road in Youngsville, Louisiana and a property on Jefferson Street in Lafayette, Louisiana that we are leasing to a third party. As a result of that decision, we have reclassified the net book value of those properties along with related mortgage notes are reflected as assets and liabilities held for sale in the balance sheets. All such amounts are included in the land and hospitality segment. We expect the sale of those properties to occur in the fiscal year ending June 30, 2018 and have, accordingly, presented the held for sale assets and liabilities as current. The comparable June 30, 2016 balances have also been reclassified held for sale related assets and liabilities. Based on the present real estate market and discussions with brokers, no impairment of the recorded amounts has occurred as of June 30, 2017. We are also pursuing the sale of our real estate limited partnership investment, but we cannot conclude such a transaction would occur within one year and, therefore, have not reclassified related assets and liabilities as held for sale. Effective July 1, 2017, the Chemin Metairie Road property is leased under a one-year term at a rent of $1,500 per month. The lessee has an option to purchase the property during the lease for the lesser of $300,000 or the average of two independent appraisals. Although, there is no certainty that such sale will occur, we do believe the lessee will exercise that purchase option. The tenant that leases the Jefferson Street property has renewed that lease through December 31, 2022 as a rent of $3,500 per month. We continue to offer that property for sale and expect a sale to occur in our 2018 fiscal year.
Income Taxes	Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes,
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, At June 30, 2017, including accrued but unpaid interest, there were 39,075,990 shares issuable upon conversion of the notes. Also at June 30, 2017, including accrued but unpaid dividends, there were potentially 105,295,000 shares issuable upon the conversion of the Series A Preferred Stock and, including accrued but unpaid dividends, there were potentially 133,911,979 shares issuable upon the conversion of the Series B Preferred stock. The shares to be issued upon conversion of the warrants and the shares issuable from the conversion of the notes and the Series A and Series B Preferred stock have been excluded from earnings per share calculations because these shares are anti-dilutive.
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Financial Instruments	Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company had marketable securities with a fair market value of $339,032 at June 30, 2016 which are all publicly traded securities with quoted prices in active markets. The fair value is based on Level 1 assumptions. The Company held no marketable securities as of June 30, 2017. The Company’s financial instruments consist principally of cash, marketable securities, accounts receivable, accounts payable and accrued liabilities, debt, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. We do not expect that adoption will have a material impact on our financial position, results of operations, cash flows or disclosures. Debt Issuance Costs In April 2015, the FASB issued new guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. Therefore, the amortization of such costs will continue to be calculated using the interest method and be reported as interest expense. The new guidance does not specifically address, and therefore does not affect, the balance sheet presentation of debt issuance costs for revolving debt arrangements. This new guidance was effective for the Company in the first quarter of fiscal 2017, and applied on a retrospective basis. To date, our unamortized debt issuance cost was $42,914 and $34,791 as of June 30, 2017 and 2016, respectively. As the Company continues to raise capital to execute its growth strategy, the use of debt in the future may have additional issuance costs to be accounted for under this guidance. Leases In February 2016, the FASB issued ASU 2016-02, Leases

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Activities	MEDICAL Twelve months ended LAND & DEVICE & OTHER June 30, 2017 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 39,000 $ 1,631,488 $ - $ - $ 1,670,488 Operating revenues, net $ 39,000 $ 890,859 $ - $ - $ 929,859 Operating income (loss) $ (2,223 ) $ 191,291 $ (32,732 ) $ (484,251 ) $ (327,915 ) Interest expense $ 27,221 $ 769 $ - $ 40,094 $ 68,084 Depreciation and amortization $ 15,666 $ 97,063 $ - $ - $ 112,729 Identifiable assets $ 1,381,622 $ 739,567 $ 240 $ 789,896 $ 2,911,325 MEDICAL Twelve months ended LAND & DEVICE & OTHER June 30, 2016 HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues, gross $ 24,700 $ - $ 4,750 $ - $ 29,450 Operating income (loss) $ (5,364 ) $ (521,025 ) $ (22,881 ) $ (864,952 ) $ (1,414,222 ) Interest expense $ 9,843 $ - $ - $ 25,346 $ 35,189 Depreciation and amortization $ 18,479 $ 68,664 $ - $ - $ 87,143 Identifiable assets $ 1,396,780 $ 917,902 $ 5,529 $ 1,318,605 $ 3,638,816

Nature of Operations and Cont20

Nature of Operations and Continuance of Business (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidated net loss	$ 407,681	$ 1,267,960
Revenue	929,859	29,450
Net cash used in operating activities	154,640	1,172,960
Cash	53,939	727,631	$ 900
Working capital deficit	639,161
Accumulated deficit	$ 3,243,543	$ 2,646,026

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Marketable securities, amortized cost basis		$ 339,032
Gross unrealized losses		38,860
Trade date receivables		302,288
Allowance for doubtful accounts
Potentially anti - dilutive shares excluded from computation of loss per share		7,452,959
Number of warrants exercised	3,726,480
Incremental common shares issuable upon conversion of debt Securities	39,075,990
Marketable securities, at market value		$ 339,032
Debt issuance cost	$ 42,914	$ 34,791
5% Series A Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock	105,295,000
5% Series B Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock	133,911,979
Chemin Metairie Road [Member]
Property lease term	1 year
Lease rent	$ 1,500
Payments to acquire property on lease	300,000
Jefferson Street [Member]
Lease rent	$ 3,500
Renewed lease term	Dec. 31, 2022
Building [Member]
Useful life	20 years
Minimum [Member] | Building Improvements [Member]
Useful life	5 years
Maximum [Member]
Equity method ownership percentage	20.00%
Maximum [Member] | Building Improvements [Member]
Useful life	10 years
Subsidiaries [Member] | Minimum [Member]
Percentage of ownership	50.00%
Equity method ownership percentage	20.00%
Subsidiaries [Member] | Maximum [Member]
Equity method ownership percentage	50.00%

Other Assets (Details Narrative

Other Assets (Details Narrative) - USD ($)	Apr. 12, 2017	Dec. 31, 2015	Jun. 30, 2017	Sep. 26, 2016	Jun. 30, 2016	Mar. 23, 2016
Intangible assets related to licenses			$ 528,583		$ 170,687
EcoGen Preferred Stock [Member]
Consideration transferred amount			300,000
Marlin USA Energy Partners LLC (Minority owner of Tigress Energy Partners, LLC) [Member]
Percentage of ownership				25.00%
Cash investment			$ 70,000
Percentage of interest			3.50%
Investment sold	$ 70,000
Transfer Agreement [Member] | September 12, 2017 [Member] | EcoGen Preferred Stock [Member]
Consideration transferred amount			$ 30,000
Other consideration in exchange approximately			$ 370,000
Beechwood Properties, LLC [Member]
Number of units acquired		280,000
Percentage of membership interest acquired		2.00%
Consideration transferred amount		$ 625,000
Number of shares issued upon acquisition		625
EcoGen Europe Limited ("EcoGen") [Member]
Percentage of ownership						25.00%
EcoGen Europe Limited ("EcoGen") [Member] | Transfer Agreement [Member] | September 12, 2017 [Member]
Increased percentage of ownership			75.00%
Scarlett Pharma Ltd ("Scarlett") [Member] | Transfer Agreement [Member] | September 12, 2017 [Member]
Additional number of shares to be surrendered			10,000,000
EcoGen [Member]
Intangible assets related to licenses			$ 450,000
Intangible assets, useful life			20 years

Loan and Insurance Note Payab23

Loan and Insurance Note Payable (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Loans Payable [Abstract]
Insurance notes payable	$ 7,225	$ 14,178

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016
Line of credit converted into preferred stock		$ 250,000	$ 100,000
Due to related party		35,000
EcoGen Preferred Stock [Member]
Consideration transferred amount		$ 300,000
Number of common stock shares outstanding and other consideration		10,000,000
EcoGen [Member]
Total cost of sales		$ 1,241,000
Sales discount		968,000
Sales discount considered an accounts receivable	$ 370,000
Preferred Stock [Member]
Line of credit converted into preferred stock		$ 250,000
5% Series B Preferred Stock [Member]
Preferred stock, stated value per share		$ 1,071.30
Series A Preferred Stock [Member]
Preferred stock, stated value per share		$ 1,072.12
Line of Credit [Member]
Commercial note line of credit		$ 250,000
Line of Credit [Member] | 5% Series B Preferred Stock [Member]
Line of credit interest rate		5.00%
Line of credit maturity date		Mar. 31, 2018
Line of Credit [Member] | Series A Preferred Stock [Member]
Preferred stock, stated value per share		$ 1,000

Long-Term Debt, Debentures an25

Long-Term Debt, Debentures and Line of Credit (Details Narrative)	12 Months Ended
	Jun. 30, 2017USD ($)days$ / sharesshares	Jun. 30, 2016USD ($)
Line of credit outstanding		$ 1,000,495
5% Convertible Notes Payable [Member]
Convertible promissory note principal	$ 1,000,000
Description of maturity	The Convertible Notes mature on the fifth anniversary of the date of issuance
Common stock conversion price | $ / shares	$ 0.015
Convertible promissory notes interest rate	5.00%
Description of call feature	Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes.
Debt instrument, convertible threshold percentage of stock price trigger	300.00%
Debt instrument, convertible threshold trading days | days	5
Convertible debt conversion value	$ 586,140
Deferred financing costs and beneficial conversion	462,384
Interest paid in kind	$ 36,140
Number of converted shares | shares	39,075,990
Line of Credit Due Upon Demand [Member] | Bank [Member]
Line of credit maximum borrowing capacity		$ 1,000,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Feb. 16, 2016	Nov. 12, 2015	Nov. 30, 2014	Jun. 30, 2017	Jun. 30, 2016	Oct. 13, 2015
Preferred stock, authorized				5,000	5,000	5,000
Common Stock, authorized				450,000,000	450,000,000
Number of warrants exercised				3,726,480
Private Equity Sale [Member]
Number of shares on private equity sale			14,905,918
Proceeds on sale of private equity			$ 49,900
Private Equity Sale [Member] | Warrant [Member]
Number of outstanding warrants				7,452,959
Exercise price of warrants				$ 0.005
Number of warrants exercised				3,726,480
Series A 5% Convertible Preferred Stock [Member]
Preferred stock, authorized		2,750
Preferred stock, stated value		$ 1,000
Preferred stock cumulative dividend rate		5.00%
Preferred stock voting rights		Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share		$ 0.015
Series B 5% Convertible Preferred Stock [Member]
Preferred stock, authorized	1,250
Preferred stock, stated value	$ 1,000
Preferred stock cumulative dividend rate	5.00%
Preferred stock voting rights	Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share	$ 0.01
Minimum [Member]
Common Stock, authorized						375,000,000
Maximum [Member]
Common Stock, authorized						450,000,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Net operating losses carryforwards	$ 2,800,000	$ 2,300,000
Income tax future year description	Net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2037.
Deferred tax assets operating loss carryforwards	$ 1,000,000	$ 800,000
Percentage of deferred tax assets valuation allowance	100.00%
Deferred tax assets

Segment Information (Details Na

Segment Information (Details Narrative)	12 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of operating segments	3

Segment Information - Schedule

Segment Information - Schedule of Segment Activities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating revenues, net	$ 929,859	$ 29,450
Operating income (loss)	(327,915)	(1,414,222)
Interest expense	68,084	35,189
Depreciation and amortization	112,729	87,143
Identifiable assets	2,911,325	3,638,816
Operating Segment [Member]
Operating revenues, gross	1,670,488	29,450
Operating revenues, net	929,859
Operating income (loss)	(327,915)	(1,414,222)
Interest expense	68,084	35,189
Depreciation and amortization	112,729	87,143
Identifiable assets	2,911,325	3,638,816
Land & Hospitality [Member] | Operating Segment [Member]
Operating revenues, gross	39,000	24,700
Operating revenues, net	39,000
Operating income (loss)	(2,223)	(5,364)
Interest expense	27,221	9,843
Depreciation and amortization	15,666	18,479
Identifiable assets	1,381,622	1,396,780
Medical Device & Pharma [Member] | Operating Segment [Member]
Operating revenues, gross	1,631,488
Operating revenues, net	890,859
Operating income (loss)	191,291	(521,025)
Interest expense	769
Depreciation and amortization	97,063	68,664
Identifiable assets	739,567	917,902
Other Services [Member] | Operating Segment [Member]
Operating revenues, gross		4,750
Operating revenues, net
Operating income (loss)	(32,732)	(22,881)
Interest expense
Depreciation and amortization
Identifiable assets	240	5,529
Corporate [Member] | Operating Segment [Member]
Operating revenues, gross
Operating revenues, net
Operating income (loss)	(484,251)	(864,952)
Interest expense	40,094	25,346
Depreciation and amortization
Identifiable assets	$ 789,896	$ 1,318,605

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Oct. 31, 2017USD ($)shares
EcoGen [Member]
Additionally in exchange for assumption approximately	$ 370,000
Number of common stock shares issued | shares	10,000,000
Other consideration	$ 300,000
Transfer Agreement [Member] | Scarlett Pharma Ltd ("Scarlett") [Member]
Increased percentage of ownership	75.00%